A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Study Overview
=================
Brief Summary
-----------------
This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

Detailed Description
-----------------
This open-label, randomized study compared the efficacy and safety of the Bruton's Tyrosine Kinase (BTK) inhibitors BGB-3111 and ibrutinib in participants with Waldenström's Macroglobulinemia who require therapy. Participants had baseline bone marrow samples assayed for sequencing of the MYD88 gene. 201 participants with the MYD88 mutation were enrolled and randomized to receive 160 mg BGB-3111 orally twice per day (PO BID) (treatment Arm A) or to receive 420mg ibrutinib orally once per day (PO QD) (treatment Arm B) until disease progression or unacceptable toxicity.

Official Title
-----------------
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)

Conditions
-----------------
Waldenström's Macroglobulinemia

Intervention / Treatment
-----------------
* Drug: BGB-3111
* Drug: Ibrutinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Clinical and definitive histologic diagnosis of WM Measurable disease, requiring treatment Participants with no prior therapy for WM, must be considered inappropriate candidates for treatment with a standard chemoimmunotherapy regimen Age ≥ 18 years old Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 Adequate bone marrow function Adequate renal and hepatic function Electrocardiogram/multigated acquisition scan (ECHO/MUGA) demonstrating left ventricular ejection fraction (LVEF)≥ the lower limit of institutional normal Participants may be enrolled who relapse after autologous stem cell transplant if they are at least 3 months after transplant, and after allogeneic transplant if they are at least 6 months post-transplant. Females of childbearing potential must agree to use highly effective forms of birth control throughout the course of the study and at least up to 90 days after last dose of study drug. Males must have undergone sterilization- vasectomy, or utilize a barrier method Life expectancy of > 4 months Key Exclusion Criteria: Prior exposure to a BTK inhibitor Evidence of disease transformation at the time of study entry Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy given with antineoplastic intent, targeted therapy, or radiation therapy within 3 weeks, or antibody-based therapy within 4 weeks of the start of study drug Major surgery within 4 weeks of study treatment Toxicity of ≥ Grade 2 from prior anticancer therapy History of other active malignancies within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally with curative intent Currently active, clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease within 6 months of screening QTcF prolongation (defined as a QTcF > 480 msec) Active, clinically significant Electrocardiogram (ECG) abnormalities Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction Uncontrolled active systemic infection or recent infection requiring parenteral anti-microbial therapy Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C Pregnant or lactating women Any life-threatening illness, medical condition, organ system dysfunction, need for profound anticoagulation, or bleeding disorder, which, in the investigator's opinion, could compromise the subject's safety Any medications which are strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or strong CYP3A inducers NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm A : Ibrutinib<br>Participants with the MYD88 mutation received Ibrutinib | Drug: Ibrutinib<br>* 420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor<br>* Other names: IMBRUVICA;|
| Active Comparator: Arm B: Zanubrutinib<br>Participants with the MYD88 mutation received zanubrutinib | Drug: BGB-3111<br>* 160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor<br>* Other names: Brukinsa;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC) | Percentage of participants with CR, defined as normal serum immunoglobulin M (IgM) levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values. | Up to approximately 2 years and 7 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC | MRR defined as the percentage of participants achieving a best response of response of CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) defined as ≥50% reduction of serum IgM from baseline. | Up to approximately 2 years and 7 months | 
| Duration of Response (DOR) as Assessed by IRC | DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first. CR is defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, is defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) is defined as ≥50% reduction of serum IgM from baseline. | Up to approximately 2 years and 7 months | 
| DOR as Assessed by IRC: Event -Free Rate | Estimated percentage of participants who were event-free based on Kaplan-Meier method. | 12 and 18 months from the date of randomization (up to approximately 2 years and 7 months) | 
| Percentage of Participants Achieving Either CR or VGPR in as Assessed by the Investigator | Percentage of participants with CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at Baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values. | Up to approximately 5 years and 5 months | 
| DOR as Assessed by the Investigator | DOR is defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first | Up to approximately 5 years and 5 months | 
| DOR as Assessed by the Investigator: Event-Free Rate | Estimated percentage of participants who were event-free based on Kaplan-Meier method. | 24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months) | 
| Progression Free Survival (PFS) as Assessed by the IRC | PFS as assessed by the IRC, defined as time from randomization to the first documentation of progression (per modified International Workshop on Waldenström macroglobulinemia [IWWM criteria]) or death, whichever occurs first | Up to approximately 2 years and 7 months | 
| PFS as Assessed by IRC: Event-Free Rate | Estimated percentage of participants who were event-free based on Kaplan-Meier method | 12 and 18 months from the date of randomization (up to approximately 2 years and 7 months) | 
| PFS as Assessed by the Investigator | PFS as assessed by the Investigator, defined as time from randomization to the first documentation of progression (per modified IWWM criteria) or death, whichever occurs first. | Up to approximately 5 years and 5 months | 
| PFS as Assessed by the Investigator: Event-Free Rate | Percentage of participants who were event-free based on Kaplan-Meier method. | 24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months) | 
| Percentage of Participants With Resolution of All Treatment-precipitating Symptoms |  | Up to approximately 5 years and 5 months | 
| Percentage of Participants With an Anti-Lymphoma Effect | Anti-Lymphoma Effect is defined as any reduction in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by CT scan, at any time during the course of study treatment. | Up to approximately 5 years and 5 months | 
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) |  | Up to approximately 5 years and 5 months |